Literature DB >> 27048897

Probiotics and prebiotics in ulcerative colitis.

Lauranne A A P Derikx1, Levinus A Dieleman2, Frank Hoentjen3.   

Abstract

The intestinal microbiota is one of the key players in the etiology of ulcerative colitis. Manipulation of this microflora with probiotics and prebiotics is an attractive strategy in the management of ulcerative colitis. Several intervention studies for both the induction and maintenance of remission in ulcerative colitis patients have been performed. Most of these studies evaluated VSL#3 or E. Coli Nissle 1917 and in general there is evidence for efficacy of these agents for induction and maintenance of remission. However, studies are frequently underpowered, lack a control group, and are very heterogeneous investigating different probiotic strains in different study populations. The absence of well-powered robust randomized placebo-controlled trials impedes the widespread use of probiotics and prebiotics in ulcerative colitis. However, given the promising results that are currently available, probiotics and prebiotics may find their way to the treatment algorithm for ulcerative colitis in the near future.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Microbiota; Prebiotics; Probiotics; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27048897     DOI: 10.1016/j.bpg.2016.02.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  25 in total

Review 1.  Changes of intestinal microbiota and microbiota-based treatments in IBD.

Authors:  Qianyu Li; Siyu Zhou; Yanna Wang; Jing Cong
Journal:  Arch Microbiol       Date:  2022-07-01       Impact factor: 2.552

2.  Probiotic Microorganisms Inhibit Epithelial Cell Internalization of Botulinum Neurotoxin Serotype A.

Authors:  Tina I Lam; Christina C Tam; Larry H Stanker; Luisa W Cheng
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

Review 3.  Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases.

Authors:  Julio Plaza-Díaz; Francisco Javier Ruiz-Ojeda; Laura Maria Vilchez-Padial; Angel Gil
Journal:  Nutrients       Date:  2017-05-28       Impact factor: 5.717

4.  Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 Attenuate Gardnerella vaginalis-Infected Bacterial Vaginosis in Mice.

Authors:  Se-Eun Jang; Jin-Ju Jeong; Su-Young Choi; Hyunji Kim; Myung Joo Han; Dong-Hyun Kim
Journal:  Nutrients       Date:  2017-05-23       Impact factor: 5.717

5.  Stachyose modulates gut microbiota and alleviates dextran sulfate sodium-induced acute colitis in mice.

Authors:  Liwen He; Feiran Zhang; Zhengyang Jian; Jiachen Sun; Jiamin Chen; Vuekhang Liapao; Qing He
Journal:  Saudi J Gastroenterol       Date:  2020 May-Jun       Impact factor: 2.485

6.  VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice.

Authors:  Chun-Sai-Er Wang; Wen-Bin Li; Hong-Ying Wang; Yi-Ming Ma; Xin-Hua Zhao; Hong Yang; Jia-Ming Qian; Jing-Nan Li
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

7.  Production Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation.

Authors:  Benedetta Cinque; Cristina La Torre; Francesca Lombardi; Paola Palumbo; Michel Van der Rest; Maria Grazia Cifone
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

8.  Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?

Authors:  Valerio Nobili; Lorenza Putignani; Antonella Mosca; Federica Del Chierico; Pamela Vernocchi; Anna Alisi; Laura Stronati; Salvatore Cucchiara; Marco Toscano; Lorenzo Drago
Journal:  Arch Med Sci       Date:  2016-09-06       Impact factor: 3.318

Review 9.  Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends.

Authors:  Mohammad Al Mijan; Beong Ou Lim
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

10.  Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway.

Authors:  Hui Wang; Shuhua Li; Houzhong Li; Fengxia DU; Jie Guan; Yanmin Wu
Journal:  Iran J Public Health       Date:  2019-07       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.